Management of induction failures in newly diagnosed transplant-eligible multiple myeloma.
作者信息
Gertz Morie A
机构信息
Division of Hematology, Mayo Clinic, Rochester, MN, USA.
出版信息
Leuk Lymphoma. 2020 Jan;61(1):1-3. doi: 10.1080/10428194.2019.1663424. Epub 2019 Sep 10.
Abstract
摘要
相似文献
1
Management of induction failures in newly diagnosed transplant-eligible multiple myeloma.
Leuk Lymphoma. 2020 Jan;61(1):1-3. doi: 10.1080/10428194.2019.1663424. Epub 2019 Sep 10.
2
[Bortezomib-based induction therapy followed by autologous hematopoietic stem cell transplantation in multiple myeloma].
Zhonghua Nei Ke Za Zhi. 2014 Nov;53(11):865-72.
3
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Lancet Haematol. 2020 Jun;7(6):e456-e468. doi: 10.1016/S2352-3026(20)30099-5. Epub 2020 Apr 30.
4
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.
Lancet. 2010 Dec 18;376(9758):2075-85. doi: 10.1016/S0140-6736(10)61424-9. Epub 2010 Dec 9.
5
Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
Lancet Haematol. 2018 Dec;5(12):e628-e640. doi: 10.1016/S2352-3026(18)30174-1.
6
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.
Lancet Haematol. 2020 Dec;7(12):e861-e873. doi: 10.1016/S2352-3026(20)30323-9.
7
Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma.
J Cancer Res Clin Oncol. 2015 Nov;141(11):2013-22. doi: 10.1007/s00432-015-1984-4. Epub 2015 May 15.
8
Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
Jpn J Clin Oncol. 2009 Jul;39(7):449-55. doi: 10.1093/jjco/hyp046. Epub 2009 Jun 1.
9
Efficacy and Safety of a Weekly Cyclophosphamide-Bortezomib-Dexamethasone Regimen as Induction Therapy Prior to Autologous Stem Cell Transplantation in Japanese Patients with Newly Diagnosed Multiple Myeloma: A Phase 2 Multicenter Trial.
Acta Haematol. 2019;141(2):111-118. doi: 10.1159/000495338. Epub 2019 Feb 6.
10
LDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimens.
Eur J Haematol. 2015 Apr;94(4):330-5. doi: 10.1111/ejh.12434. Epub 2014 Oct 18.
本文引用的文献
1
Salvage therapy versus upfront autologous stem cell transplantation in multiple myeloma patients with progressive disease after first-line induction therapy.
Leuk Lymphoma. 2020 Jan;61(1):27-36. doi: 10.1080/10428194.2019.1646905. Epub 2019 Aug 19.
2
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol. 2019 Jan;20(1):57-73. doi: 10.1016/S1470-2045(18)30687-9. Epub 2018 Dec 14.
3
Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
Lancet. 2017 Feb 4;389(10068):519-527. doi: 10.1016/S0140-6736(16)31594-X. Epub 2016 Dec 23.
4
Primary failure of bortezomib in newly diagnosed multiple myeloma--understanding the magnitude, predictors, and significance.
Leuk Lymphoma. 2016;57(6):1382-8. doi: 10.3109/10428194.2015.1121258. Epub 2016 Jan 4.
5
Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma.
Biol Blood Marrow Transplant. 2015 Feb;21(2):335-41. doi: 10.1016/j.bbmt.2014.10.023. Epub 2014 Nov 1.
6
Impact of failed response to novel agent induction in autologous stem cell transplantation for multiple myeloma.
Ann Hematol. 2014 Apr;93(4):627-34. doi: 10.1007/s00277-013-1911-1. Epub 2013 Oct 2.
7
Association of response endpoints with survival outcomes in multiple myeloma.
Leukemia. 2014 Feb;28(2):258-68. doi: 10.1038/leu.2013.220. Epub 2013 Jul 19.
8
The response to second-line induction with bortezomib and dexamethasone is predictive of long-term outcomes prior to high-dose chemotherapy with autologous stem cell transplantation for multiple myeloma.
Intern Med. 2013;52(9):961-8. doi: 10.2169/internalmedicine.52.9385. Epub 2012 Mar 1.
9
Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction.
Blood. 2010 Mar 25;115(12):2348-53; quiz 2560. doi: 10.1182/blood-2009-07-235531. Epub 2010 Jan 20.
Zotero 插件